Regeneron Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

REGN Regeneron Pharmaceuticals Inc

NSC Norfolk Southern Corp

WM Waste Management Inc

ITOS Iteos Therapeutics Inc

CCLD CareCloud Inc

JEF Jefferies Financial Group Inc

RSASF Resaas Services Inc

VRNT Verint Systems Inc

TRHC Tabula Rasa HealthCare Inc

ILMN Illumina Inc

Go

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.